{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:00:11Z","timestamp":1790442011454,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Study objectives<\/jats:title><jats:p>Recent treatment guidelines for chronic insomnia recommend pharmacological and non-pharmacological therapies. One of the contemporary drug options for insomnia includes dual orexin receptor antagonist (DORA), such as suvorexant and lemborexant. We conducted a systematic review and meta-analysis for the treatment of insomnia with suvorexant and lemborexant based on randomized, double-blind, placebo-controlled Trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a comprehensive search on three databases (PubMed\/Medline, Web of Science, and Cochrane Library) till August 14, 2021, without any restrictions to retrieve the relevant articles. The effect sizes were computed presenting the pooled mean difference or risk ratio along with 95% confidence interval of each outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our search showed eight articles (five for suvorexant and three for lemborexant). Results of diary measures, rating scales, polysomnography results, treatment discontinuation, and adverse events were measured. All efficacy outcome measures favorably and significantly differed in the suvorexant compared to placebo. Safety profile did not differ significantly except for somnolence, excessive daytime sleepiness\/sedation, fatigue, back pain, dry mouth, and abnormal dreams. Important adverse events including hallucinations, suicidal ideation\/behavior and motor vehicle accidents did not differ between suvorexant and placebo. All the efficacy outcomes significantly differed between lemborexant 5 and lemborexant 10 compared to placebo. Somnolence rate for lemborexant 5 and lemborexant 10 and nightmare for lemborexant 10 were significantly higher than placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present meta-analysis reported that suvorexant and lemborexant are efficacious and safe agents for the patients with insomnia. Further data in patients with insomnia and various comorbid conditions are needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2022.1070522","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:23:13Z","timestamp":1670822593000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant"],"prefix":"10.3389","volume":"13","author":[{"given":"Habibolah","family":"Khazaie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Khazaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Hirshkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Sharafkhaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.5664\/jcsm.26929","article-title":"Insomnia: definition, prevalence, etiology, and consequences.","author":"Roth","year":"2007","journal-title":"J Clin Sleep Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.smrv.2018.10.006","article-title":"Insomnia as a predictor of mental disorders: a systematic review and meta-analysis.","volume":"43","author":"Hertenstein","year":"2019","journal-title":"Sleep Med Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jad.2014.07.020","article-title":"Insomnia before and after treatment for anxiety and depression.","volume":"168","author":"Mason","year":"2014","journal-title":"J Affect Disord."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070228","article-title":"Associations between night work and anxiety, depression, insomnia, sleepiness and fatigue in a sample of Norwegian nurses.","volume":"8","author":"\u00d8yane","year":"2013","journal-title":"PLoS One."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.577429","article-title":"Gender difference in the prevalence of insomnia: a meta-analysis of observational studies.","volume":"11","author":"Zeng","year":"2020","journal-title":"Front Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/sleep\/31.4.473","article-title":"Prevalence, course, and comorbidity of insomnia and depression in young adults.","volume":"31","author":"Buysse","year":"2008","journal-title":"Sleep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/sleep\/30.2.213","article-title":"Comorbidity of chronic insomnia with medical problems.","volume":"30","author":"Taylor","year":"2007","journal-title":"Sleep."},{"key":"B8","article-title":"The essential companion to the diagnostic and statistical manual of mental disorders: DSM-IV guidebook.","volume":"21","author":"Munro","year":"1996","journal-title":"J Psychiatry Neurosci."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1808-6","article-title":"Prevalence of insomnia symptoms and their associated factors in patients treated in outpatient clinics of four general hospitals in Guangzhou, China.","volume":"18","author":"Zheng","year":"2018","journal-title":"BMC Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.5664\/jcsm.27286","article-title":"Clinical guideline for the evaluation and management of chronic insomnia in adults.","volume":"4","author":"Schutte-Rodin","year":"2008","journal-title":"J Clin Sleep Med."},{"key":"B11","year":"1994","journal-title":"Diagnostic and Statistical Manuel of Mental Disorders."},{"key":"B12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/wps.20189","article-title":"The development of the ICD-11 clinical descriptions and diagnostic guidelines for mental and behavioural disorders.","volume":"14","author":"First","year":"2015","journal-title":"World Psychiatry."},{"key":"B13","year":"1992","journal-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1378\/chest.14-0970","article-title":"International classification of sleep disorders.","volume":"146","author":"Sateia","year":"2014","journal-title":"Chest."},{"key":"B15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine clinical practice guideline.","volume":"13","author":"Sateia","year":"2017","journal-title":"J Clin Sleep Med."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00163","article-title":"Orexin receptor antagonists as therapeutic agents for insomnia.","volume":"4","author":"Equihua","year":"2013","journal-title":"Front Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.155496","article-title":"Suvorexant: the first orexin receptor antagonist to treat insomnia.","volume":"6","author":"Dubey","year":"2015","journal-title":"J Pharmacol Pharmacother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1021\/jm100541c","article-title":"Discovery of the dual orexin receptor antagonist [(7 R)-4-(5-chloro-1, 3-benzoxazol-2-yl)-7-methyl-1, 4-diazepan-1-yl][5-methyl-2-(2 H-1, 2, 3-triazol-2-yl) phenyl] methanone (MK-4305) for the treatment of insomnia.","volume":"53","author":"Cox","year":"2010","journal-title":"J Med Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3109\/01677063.2011.566953","article-title":"Promotion of sleep by suvorexant\u2013a novel dual orexin receptor antagonist.","volume":"25","author":"Winrow","year":"2011","journal-title":"J Neurogenet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1124\/jpet.117.241422","article-title":"In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist.","volume":"362","author":"Beuckmann","year":"2017","journal-title":"J Pharmacol Exp Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jpsychires.2020.05.025","article-title":"Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis.","volume":"128","author":"Kishi","year":"2020","journal-title":"J Psychiatr Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.sleep.2018.09.010","article-title":"Effects of suvorexant on the insomnia severity index in patients with insomnia: analysis of pooled phase 3 data.","volume":"56","author":"Herring","year":"2019","journal-title":"Sleep Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.5664\/jcsm.6116","article-title":"Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials.","volume":"12","author":"Herring","year":"2016","journal-title":"J Clin Sleep Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jagp.2017.03.004","article-title":"Suvorexant in elderly patients with insomnia: pooled analyses of data from phase III randomized controlled clinical trials.","volume":"25","author":"Herring","year":"2017","journal-title":"Am J Geriatr Psychiatry."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136910","article-title":"Suvorexant for primary insomnia: a systematic review and meta-analysis of randomized placebo-controlled trials.","volume":"10","author":"Kishi","year":"2015","journal-title":"PLoS One."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.smrv.2016.09.004","article-title":"Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis.","volume":"35","author":"Kuriyama","year":"2017","journal-title":"Sleep Med Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.18553\/jmcp.2021.21011","article-title":"Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.","volume":"27","author":"McElroy","year":"2021","journal-title":"J Manag Care Spec Pharm."},{"key":"B28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/00325481.2020.1823724","article-title":"Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.","volume":"133","author":"Moline","year":"2021","journal-title":"Postgrad Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg."},{"key":"B30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited.","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials."},{"key":"B31","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease.","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst."},{"key":"B32","first-page":"461","article-title":"Efficacy and safety of suvorexant for the treatment of primary insomnia among Chinese: a 6-month randomized double-blind controlled study.","volume":"22","author":"Fan","year":"2017","journal-title":"Neurology Asia."},{"key":"B33","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/alz.12035","article-title":"Polysomnographic assessment of suvorexant in patients with probable Alzheimer\u2019s disease dementia and insomnia: a randomized trial.","volume":"16","author":"Herring","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.","volume":"43","author":"K\u00e4rpp","year":"2020","journal-title":"Sleep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.5664\/jcsm.6800","article-title":"Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study.","volume":"13","author":"Murphy","year":"2017","journal-title":"J Clin Sleep Med."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial.","volume":"2","author":"Rosenberg","year":"2019","journal-title":"JAMA Netw Open."},{"key":"B39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials.","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1185\/03007990903167415","article-title":"Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference.","volume":"25","author":"Yang","year":"2009","journal-title":"Curr Med Res Opin."},{"key":"B41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5665\/sleep.2442","article-title":"Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.","volume":"36","author":"Black","year":"2013","journal-title":"Sleep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy.","volume":"355","author":"Nishino","year":"2000","journal-title":"Lancet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0165-1781(00)00227-4","article-title":"Prevalence of hallucinations and their pathological associations in the general population.","volume":"97","author":"Ohayon","year":"2000","journal-title":"Psychiatry Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1212\/WNL.52.6.1194","article-title":"Prevalence and pathologic associations of sleep paralysis in the general population.","volume":"52","author":"Ohayon","year":"1999","journal-title":"Neurology."},{"key":"B46","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.","volume":"95","author":"Lecea","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"B47","author":"Farkas","year":"2013","journal-title":"Suvorexant Safety and Efficacy."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1070522\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:23:17Z","timestamp":1670822597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1070522\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":47,"alternative-id":["10.3389\/fpsyt.2022.1070522"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.1070522","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]},"article-number":"1070522"}}